Adagene (ADAG) announced a licensing agreement under which Third Arc Bio will utilize Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumor associated antigens. Under the terms of the agreement, Third Arc Bio will receive rights to research, develop and commercialize two candidate molecules worldwide. Adagene will receive an upfront payment of $5 million and is eligible to receive development and commercial-based milestones of up to $840 million as well as royalties on end-user sales. In addition, Adagene has a no-cost option to develop and commercialize these candidate molecules in Greater China, Singapore and South Korea.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG:
- Adagene files to sell 10.625M ordinary shares or 8.5M ADSs for holders
- Adagene says first patient dosed in Phase 2 study of muzastotug, KEYTRUDA
- Tempest Therapeutics and Adagene’s Promising Advances in Liver Cancer Treatment
- Adagene’s Innovative Cancer Study: A Potential Game-Changer in Oncology
- Adagene initiated with a Buy at Lucid Capital